stockrowBio-Techne Corp
TECH Healthcare Biotechnology
Bio-Techne Corp’s revenue for fiscal 2026 (year ended June 2026) was $1.2 billion, roughly unchanged from fiscal 2025.
- Revenue
- +1.33%
- EPS
- +418.2%
- Free cash flow
- −6.83%
- Total debt
- −42.2%
Quarter to June 2026, against a year earlier
Follow TECH
Alert me
Bio-Techne Corp (TECH) Free cash flow margin
Bio-Techne Corp's free cash flow margin over the twelve months to 30 June 2026 was 21.7%. Over the past ten years it has ranged from 19.0% (fiscal 2023) to 33.1% (fiscal 2021); the current reading is higher than 42% of that period. That is above the Biotechnology industry median of 0.00% and above the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2026 | 21.7% | 0.63 |
| FY2025 | 21.0% | 0.66 |
| FY2024 | 20.4% | 1.35 |
| FY2023 | 19.0% | (6.34) |
| FY2022 | 25.4% | (7.71) |
| FY2021 | 33.1% | 12.29 |
| FY2020 | 20.8% | (1.10) |
| FY2019 | 21.9% | (1.36) |
| FY2018 | 23.2% | 0.41 |
| FY2017 | 22.8% | (2.67) |
Against its own ten years
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| TECH Bio-Techne Corp | 21.7% |
| BMRN BioMarin Pharmaceutical Inc. compare | 15.3% |
| CAI Caris Life Sciences,�Inc. compare | 8.00% |
| TGTX TG Therapeutics, Inc. compare | 2.17% |
| PCVX Vaxcyte, Inc. compare | 0.00% |
| SMMT Summit Therapeutics PLC compare | 0.00% |
| KYMR Kymera Therapeutics, Inc. compare | 0.00% |
| TWST Twist Bioscience Corporation compare | −22.2% |
| IBRX ImmunityBio, Inc. compare | −173.8% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on TECH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement